Stress Echocardiography & Myocardial Viability

Purpose and Indications for Stress Echocardiography

Stress echocardiography combines 2D imaging with physiologic or pharmacologic stress to unmask inducible ischemia not evident at rest, to risk-stratify known coronary artery disease, and — critically for post-infarct patients — to determine whether dysfunctional myocardium is viable (able to recover function if revascularized) or has been replaced by non-contractile scar. The test relies on the same wall-motion scoring and 17-segment model taught in section 9.1; images are compared at rest and at each stress stage, side by side, in the same imaging views (typically parasternal long- and short-axis, apical four- and two-chamber).

Exercise vs. Pharmacologic Stress

• Exercise stress echo, using a treadmill or semi-supine bicycle, is preferred whenever the patient can achieve an adequate workload. Images are acquired immediately post-treadmill or continuously during bicycle exercise, targeting at least 85% of the age-predicted maximal heart rate, calculated as 220 minus age.
• Dobutamine stress echocardiography (DSE) is used when patients cannot exercise adequately — deconditioning, orthopedic or vascular limitations, recent surgery — and it is the standard technique for viability assessment, because dobutamine allows graded, staged low-to-high dose testing that exercise cannot reproduce.

Dobutamine Protocol

Dobutamine is infused in incremental stages, each lasting three to five minutes, typically progressing 5, then 10, then 20, then 30, then 40 mcg/kg/min, with atropine added at the higher stages if the target heart rate is not yet reached. Images are acquired at baseline, low dose, each intermediate stage, and peak dose. The test is terminated at target heart rate, a new or worsening wall-motion abnormality, significant arrhythmia, hypotension, or limiting symptoms such as chest pain.

Interpreting the Response Patterns

• A positive ischemic response is a new or worsening regional wall-motion abnormality appearing at a higher workload than at rest — the hallmark finding for diagnosing obstructive coronary disease.
• Low-dose dobutamine, roughly the 5 to 10 mcg/kg/min stages, is the key viability window: a dysfunctional resting segment that improves contractility at low dose indicates viable, hibernating myocardium — the segment retains enough contractile reserve to respond to gentle inotropic stimulation.
• The biphasic response — improvement at low dose followed by deterioration at a higher dose — is the single most specific pattern for viable-but-jeopardized, hibernating myocardium fed by a critically stenotic vessel, and it best predicts functional recovery of that segment after successful revascularization.
• A segment showing no change at any dose is most consistent with non-viable, transmural scar, while sustained improvement without later deterioration suggests viable myocardium supplied by a vessel that is not critically stenotic.
• Sensitivity for detecting viability is highest when "any improvement at low dose" is used as the criterion; specificity is highest when a true biphasic pattern is required before calling a segment viable.

Practical and Safety Notes

• Imaging is obtained from the standard parasternal and apical windows, using a quad-screen or side-by-side display so rest and stress images can be compared segment by segment without ambiguity.
• Relative contraindications to dobutamine include a recent acute myocardial infarction within the institutional safety window, severe uncontrolled hypertension, significant tachyarrhythmias, and severe outflow obstruction, since dobutamine's inotropic and chronotropic effects can worsen dynamic left ventricular outflow tract obstruction (see hypertrophic cardiomyopathy, section 9.5).
• Beta-blocker therapy may blunt the expected heart-rate response and often requires supplemental atropine to reach a diagnostic target heart rate; overall test accuracy depends on achieving an adequate stress workload.
• The same viability principles extend to other modalities, including nuclear perfusion imaging and cardiac MRI late gadolinium enhancement, but dobutamine stress echo remains widely used because it directly demonstrates contractile reserve rather than only perfusion or scar burden.

Clinical Impact and Pitfalls

Viability testing directly changes management. Patients with a substantial amount of viable, hibernating myocardium — commonly defined as several contiguous segments, or roughly a fifth or more of the total left ventricle, showing a low-dose or biphasic response — derive the greatest survival and ejection-fraction benefit from revascularization, since restoring flow to hibernating tissue allows it to resume normal contraction over subsequent weeks to months. Conversely, a ventricle that is predominantly scarred, with little or no contractile reserve on any segment, gains little functional benefit from revascularization and is more often managed medically, since surgery or intervention carries procedural risk without a proportionate reward.

Interpretation pitfalls are common and should be recognized. Tethering — passive motion of an adjacent normal segment pulling on a dysfunctional one — can make an akinetic segment falsely appear to move, so thickening (not just endocardial excursion) must always be assessed alongside motion. Submaximal stress, from inadequate dobutamine dosing or premature beta-blockade-limited heart-rate response, reduces sensitivity for ischemia and can produce a false-negative study. Poor endocardial border definition from suboptimal acoustic windows is a leading cause of both false positives and false negatives; ultrasound-enhancing (contrast) agents are frequently used during stress echo specifically to improve endocardial border delineation and reader confidence in equivocal studies. Because interpretation is inherently qualitative and reader-dependent, side-by-side quad-screen review and experience with the 17-segment model are essential to reproducible results.